Cisplatin/carboplatin cross-resistance in ovarian cancer
about
Systems biology of cisplatin resistance: past, present and futurePhase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.New therapies for ovarian cancer.Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenograftsIn vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.Anti-proliferative activity and mechanism of action of titanocene dichloride.Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells.Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance.Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.Highly efficient uptake into cisplatin-resistant cells and the isomerization upon coordinative DNA binding of anticancer tetrazolato-bridged dinuclear platinum(II) complexes.Investigation on pharmacokinetics, tissue distribution and excretion of a novel platinum anticancer agent in rats by inductively coupled plasma mass spectrometry (ICP-MS).The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLCQuantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter.Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry.Effect of quercetin on the genotoxic potential of cisplatin.Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
P2860
Q26863585-765F96B7-36F6-46F2-9635-910350D2FF2EQ33330193-B24AFA2C-3037-4DD4-AE11-0EB6DC26119AQ33336817-2F7DAB6E-08C7-48E4-8BCF-7ACD7AF0386EQ33494756-6D59D61A-B7CE-413F-910C-1F54E7D6A185Q34562736-B910BD11-FBAC-46D2-8214-6BA07262A2E3Q35259954-D7077BF9-6A18-4229-8AE6-9CB0E5BA31ABQ35975934-4AE969C7-556A-46AB-8343-02C2D55EDB9CQ35977240-7F6EA170-29AE-4191-84B9-A68E05E07700Q35978030-D2DC4004-51E1-4F42-94C5-B32598F77D42Q36292954-9B061B7E-D368-4687-9A25-53671338F426Q36672242-9891BA5F-D948-42E9-B58C-62994F0B0B46Q37234210-098CC371-D9C8-47AD-B615-7DE93D741813Q37249509-CDF919D4-6196-4322-8EF1-86D97E728541Q37252047-A2E51DFA-6205-4DCB-8229-3509E2F90C14Q38347735-48EB5301-FE2C-4E95-959C-41932B28291AQ38777716-8DDE5355-E75F-4BCC-AA51-EF76D610FCBCQ38833550-E48FD114-D4A1-4781-825E-5A238EF85FC5Q39024229-5A00041E-552E-4204-A6C2-A64A70DA075BQ40001235-39BBDC2B-2C19-4DA7-A2CA-922C5D060F28Q42700773-E0FB4C3E-0046-4969-8088-9EEBBAB55C49Q43544171-2AB60503-0FF4-4FDA-BA50-CFF8DF19291EQ45376186-20F84C9D-9FC1-4F55-9EF5-4E6599AE8274Q50138984-402AEB96-310C-4472-BE8D-BD47C9C72536Q54185356-8B3A0682-6609-4F65-B1D5-52A87247A6A6Q54296297-B72DB440-F2FA-4109-B83C-14EE02688A81
P2860
Cisplatin/carboplatin cross-resistance in ovarian cancer
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Cisplatin/carboplatin cross-resistance in ovarian cancer
@ast
Cisplatin/carboplatin cross-resistance in ovarian cancer
@en
type
label
Cisplatin/carboplatin cross-resistance in ovarian cancer
@ast
Cisplatin/carboplatin cross-resistance in ovarian cancer
@en
prefLabel
Cisplatin/carboplatin cross-resistance in ovarian cancer
@ast
Cisplatin/carboplatin cross-resistance in ovarian cancer
@en
P2093
P2860
P356
P1476
Cisplatin/carboplatin cross-resistance in ovarian cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1989.356
P407
P577
1989-11-01T00:00:00Z